Fig. 6

Correlations of TAP1 expression with TME biomarkers and clinical responses to immunotherapy. A Heatmap showing correlations between TAP1 expression and 47 immune regulators according to Spearman’s correlation test. B, C Correlations of TAP1 expression with TMB and MSI. D Survival analysis of patients with high (n = 66) and low (n = 232) TAP1 expression based on OS data from patients with urothelial cancer receiving anti-PDL1 immunotherapy, and proportions of patients with different therapeutic responses. E Survival analysis of patients with high (n = 29) and low (n = 3) TAP1 expression based on PFS data from patients with melanoma receiving anti-CTLA-4&PD-1 immunotherapy, and the proportions of patients with different therapeutic responses. F Survival analysis of patients with high (n = 43) and low (n = 6) TAP1 expression using OS data from patients with breast cancer receiving anti-PD-1 immunotherapy, and the proportions of patients with different therapeutic responses. G Survival analysis of patients with high (n = 23) and low (n = 18) TAP1 expression using OS data from patients with metastatic melanoma receiving anti-CTLA-4 immunotherapy, and the proportions of patients with different therapeutic responses. TMB, tumor mutation burden; MSI, microsatellite instability; PD, progressive disease; SD, stable disease; CR, complete response; PR, partial responses. The significance threshold was P < 0.05. *P < 0.05, **P < 0.01, ***P < 0.001